We serve Chemical Name:3,4,5-Tribromopyridine CAS:2457-48-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,4,5-Tribromopyridine
CAS.NO:2457-48-9
Synonyms:3,4,5-Tribromopyridin;Pyridine, 3,4,5-tribromo-;3,4,5-tribromo-pyridine;3,4,5-Tribrompyridin;3,4,5-Tribromopyridine
Molecular Formula:C5H2Br3N
Molecular Weight:315.788
HS Code:2933399090
Physical and Chemical Properties:
Melting point:106.5-107.5ºC
Boiling point:284.0±35.0 °C at 760 mmHg
Density:2.4±0.1 g/cm3
Index of Refraction:1.642
PSA:12.89000
Exact Mass:312.773712
LogP:3.28
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2811 6.1 / PGIII
Packing Group:
Contact us for information like 3,4,5-Tribromopyridin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,4,5-Tribromopyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyridine, 3,4,5-tribromo- Use and application,3,4,5-tribromo-pyridine technical grade,usp/ep/jp grade.
Related News: As far as chemical raw materials are concerned, China occupies a large share in the field of bulk raw materials and has become one of the world’s largest suppliers of chemical raw materials. 3,4,5-Tribromopyridine manufacturer Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 3,4,5-Tribromopyridine supplier The term active pharmaceutical ingredient may refer to an active chemical within an FDA-regulated drug, or API might mean the entire drug with its active and inactive ingredients. 3,4,5-Tribromopyridine vendor Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 3,4,5-Tribromopyridine factory Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.
